Arecor Therapeutics brings more subjects Phase I trial of its insulin candidate

Arecor Therapeutics has decided to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278, in line with the update provided within its Interim Results on 14 September.

The increase in the number of subjects within the study, from 32 to 42, will increase the power of the study and, in turn, increase the value of the results for patients with high insulin needs. Results are expected in early 2024.

 Sarah Howell, Chief Executive Officer at Arecor, said that having already demonstrated AT278’s very promising profile in Type 1 diabetic patients, this is a key clinical study for AT278 in the Type 2 patient population.

She said that the number of people living with Type 2 diabetes is increasing, year-on-year, driven by the obesity epidemic, and many patients are becoming insulin resistant, requiring large volumes of insulin and multiple injections to manage their condition, which is a heavy daily burden. Howell said that AT278 has the potential to be the first, and potentially only, highly concentrated and very rapid acting insulin and thereby become the gold standard insulin for those with high daily insulin needs. Howell further said that AT278 also has the potential to be a critical enabler in the development of next generation miniaturised and longer wear insulin delivery systems. “And with all three major insulin device companies having access to patch pump technology, we expect an acceleration in the development of these next generation systems, which require a concentrated rapid acting insulin,” Howell said.